Redx Pharma PLC (AIM:REDX) said a summary of the presentation on its RXC004 Porcupine inhibitor at the American Society of Clinical Oncology Annual Meeting is available for viewing.
A formal presentation of the poster by the chief investigator, Professor Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, Texas, will be made at the conference on 4 June 2022.
The poster – a method of presenting research findings succinctly at meetings and conferences – is entitled 'A Multi-arm, Phase 2, Open-Label Study to Assess the Efficacy of RXC004 as Monotherapy and in Combination with Nivolumab, in Patients with Ring Finger Protein 43 (RNF43) or R-Spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable Colorectal Cancer, following standard treatment'.
It details the design of Redx's ongoing PORCUPINE1 Phase 2 trial of RXC004 monotherapy, and RXC004 in combination with nivolumab, an anti-PD-1 antibody, in patients with advanced microsatellite stable metastatic colorectal cancer who have progressed following treatment with standard of care.
The PORCUPINE trial will explore the dual mechanism of action of RXC004 seen in the preclinical models by targeting tumour cells and reversing immune evasion.
“We continue to be excited by the potential of RXC004 to tackle a number of Wnt-ligand driven cancers with high unmet clinical need, including metastatic colorectal cancer. We look forward to progressing our proof-of-concept Phase 2 studies with this compound, where we expect to report headline data during 2023," said Dr Jane Robertson, the chief medical officer of Redx.